Summary section
Xtant Medical (NYSE:XTNT) has reported its financial results for the first quarter, exceeding analyst expectations. The company posted earnings per share (EPS) of $0.2791, which is a significant improvement from the estimated loss of $-0.0100. Revenue for the quarter reached $32.9 million, surpassing the consensus estimate of $31.58 million.
Guidance and Outlook
####################
Xtant Medical has provided guidance for its financial performance in fiscal year 2025 (FY 2025). The company anticipates revenue to range from $127 million to $131 million, which is slightly below the analyst consensus estimate of $128.3 million. This forecast suggests that Xtant Medical’s growth momentum may be moderate, but still aligned with previous trends.
Historical Stock Performance
#########################
Xtant Medical’s stock price has been under pressure in recent months, declining by -12.9% over the past three months and -36.38% over the last twelve months. The closing price of $0.52 indicates a downward trend that may continue if market conditions remain unfavorable.
Earnings Revisions
#################
Since the release of Xtant Medical’s quarterly earnings report, there have been changes in analyst estimates regarding the company’s financial performance. Specifically, for the fiscal year ended (FY) 2025. Xtant Medical has seen one positive EPS revision and zero negative revisions over the past ninety days. This dynamic change is likely due to evolving market expectations, reflecting shifting investor sentiment.
Institutional Support
####################
The overall health of Xtant Medical’s financial situation can be evaluated through tools like InvestingPro’s Financial Health score, which provides a holistic view of the company’s financial standing. In contrast to its overall downward trajectory in stock price, Xtant Medical’s Financial Health Score indicates "good performance", suggesting some resilience within the company.
Comparative Analysis
#####################
Xtant Medical has not released any recent earnings data in comparison to a similar stock as I’ve taken the summary from multiple sources and rewritten for this document. To make an accurate assessment about whether XTNT is undervalued or overvalued, various fundamental analysis methods and comparable companies can provide useful insights.
Valuation Analysis
#################
To more deeply understand the current value of Xtant Medical’s shares in relation to its industry counterpart’s, it would be best to analyze using a comprehensive methodology. Some tools for accomplishing this are available through investing platforms like Stockscore or through third-party data providers such as Refinitiv (previously Thomson Reuters Financial & Risk).
Conclusion
###########
Xtant Medical has posted mixed financial results, exceeding revenue expectations while underperforming its stock price in comparison to previous periods. Analyzing changes in EPS revisions and the overall outlook may offer insights for investors looking for indicators of long-term growth or decline.